Secretome Therapeutics: Pioneering nCPC-Based Cardiovascular Therapies
  • Home
  • Pipeline
  • Leadership
  • News & Publications
    • News
    • Publications
Select Page

Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21

by secretome | Oct 28, 2024 | Investors, News

DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC...

Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting

by secretome | May 16, 2023 | Investors, News

[DALLAS, TX – May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...

Recent Posts

  • Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
  • Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
  • Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
  • Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
  • Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21
© 2025 Secretome Therapeutics | Brady UX